ArticleCureus2025
Substance Use Treatment Services in New York (2021-2023): A State Profile Analysis Based on National Survey of Substance Abuse and Mental Health Services (N-SUMHSS) Data.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubstance use disorders (SUDs) are a significant public health issue in the U.S., with New York State facing rising treatment demands. The National Survey of Substance Abuse and Mental Health Services (N-SUMHSS) offers valuable data on treatment trends across the state.
objectiveThis study analyzes trends in substance use treatment services in New York from 2021 to 2023 using N-SUMHSS data, focusing on facility capacity, medication-assisted treatment (MAT) utilization, and treatment effectiveness.
methodsSecondary data from the N-SUMHSS (2021-2023) were analyzed, examining facility types, client numbers, and MAT use (methadone, buprenorphine, naltrexone). Descriptive statistics and trend analysis were conducted to assess changes in treatment services.
resultsFrom 2021 to 2023, the number of facilities remained stable, with slight fluctuations. Private non-profit organizations dominated, comprising 69.7% of facilities in 2022-2023. MAT utilization declined in both opioid treatment programs (OTPs) and non-OTP facilities, with methadone usage remaining prevalent. Clients receiving MAT at OTP facilities decreased from 39,534 (9.3%) in 2021 to 34,186 (7.8%) in 2023, while naltrexone use rose. Outpatient services increased to 547 (72.1%), while residential and hospital inpatient facilities saw slight declines.
conclusionMAT utilization has improved, but challenges persist in addressing the growing demand for residential and detox services. Expanding outpatient and inpatient services, along with greater access to MAT, is crucial to improving treatment in New York.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.